1. 2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC). (September 2015) Authors: McDermott, D.F.; Infante, J.R.; Chowdhury, S.; Voss, M.H.; Motzer, R.J.; Perini, R.F.; Morosky, A.; Zheng, F.F.; White, B.C.; Wang, Q.; Jewell, R.C.; Rini, B.I. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). (September 2015) Authors: Sharma, P.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; Castellano, D.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T.C.; Ueda, T.; Xu, L.A.; Waxman, I.M.; Motzer, R.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 501 Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial. (September 2015) Authors: George, S.; Motzer, R.J.; Hammers, H.; Redman, B.; Kuzel, T.; Tykodi, S.S.; Plimack, E.; Jiang, J.; Waxman, I.; Rini, B.I. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. (June 2016) Authors: Belum, V.R.; Benhuri, B.; Postow, M.A.; Hellmann, M.D.; Lesokhin, A.M.; Segal, N.H.; Motzer, R.J.; Wu, S.; Busam, K.J.; Wolchok, J.D.; Lacouture, M.E. Journal: European journal of cancer Issue: Volume 60(2016) Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study. (February 2017) Authors: Grande, E.; Choueiri, T.K.; Motzer, R.J.; Escudier, B.; Pal, S.; Kollmannsberger, C.; Pikiel, J.; Gurney, H.; Rha, S.Y.; Park, S.H.; Geertsen, P.F.; Gross Goupil, M.; Suarez, C.; Arroyo, A.; Dean, M.; George, D.; Powles, T. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study. (February 2017) Authors: Bracarda, S.; Choueiri, T.K.; Powles, T.; Motzer, R.J.; Olencki, T.; Frontera, O.A.; Oudard, S.; Rolland, F.; Tomczak, P.; Castellano, D.; Appleman, L.; Drabkin, H.; Vaena, D.; Milwee, S.; Youkstetter, J.; Escudier, B. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. (1st June 2017) Authors: Zarbo, A.; Belum, V.R.; Sibaud, V.; Oudard, S.; Postow, M.A.; Hsieh, J.J.; Motzer, R.J.; Busam, K.J.; Lacouture, M.E. Journal: British journal of dermatology Issue: Volume 176:Number 6(2017) Page Start: 1649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. (24th April 2017) Authors: Zarbo, A.; Belum, V.R.; Sibaud, V.; Oudard, S.; Postow, M.A.; Hsieh, J.J.; Motzer, R.J.; Busam, K.J.; Lacouture, M.E. Journal: British journal of dermatology Issue: Volume 176:Number 6(2017) Page Start: 1649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. (June 2019) Authors: Shah, A.Y.; Kotecha, R.R.; Lemke, E.A.; Chandramohan, A.; Chaim, J.L.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M.T.; Zurita, A.J.; Wang, J.; Corn, P.G.; Jonasch, E.; Motzer, R.J.; Sharma, P.; Voss, M.H.; Tannir, N.M. Journal: European journal of cancer Issue: Volume 114(2019) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). (February 2017) Authors: Schmidinger, M.; Motzer, R.J.; Powles, T.; Escudier, B.; Tannir, N.M.; Mainwaring, P.N.; Rini, B.I.; Hammers, H.J.; Donscov, F.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.Y.C.; Aftab, D.T.; Hessel, C.; Scheffold, C.; Schwab, G.; Pal, S.; Hutson, T.E.; Choueiri, T.K. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗